论文部分内容阅读
目的探讨不同剂量阿托伐他汀对新疆维吾尔族急性冠脉综合征患者血清高敏C反应蛋白水平(hs-CRP)的影响。方法将89例择期行冠脉介入治疗的维吾尔族急性冠脉综合征患者随机分为阿托伐他汀常规治疗组(对照组,20mg/d,45例)和阿托伐他汀强化治疗组(试验组,40mg/d,44例),观察治疗后4周两组患者血清高敏C反应蛋白水平(hs-CRP)。结果两组患者4周后血清hs-CRP水平均有不同程度下降,且试验组hs-CRP水平显著低于治疗前及对照组同期检测值(P<0.01)。结论阿托伐他汀可明显降低维吾尔族急性冠脉综合征患者血清hs-CRP水平,调脂强度与维吾尔族急性冠脉综合征患者血清hs-CRP浓度的下降趋势相关。
Objective To investigate the effects of different doses of atorvastatin on serum high-sensitivity C-reactive protein (hs-CRP) levels in patients with Uygur acute coronary syndromes in Xinjiang. Methods Eighty-nine patients with Uighur acute coronary syndrome who underwent coronary intervention were randomly divided into the atorvastatin treatment group (control group, 20 mg / d, 45 cases) and atorvastatin treatment group Group, 40mg / d, 44 cases). The levels of hs-CRP in the two groups were observed 4 weeks after treatment. Results The levels of hs-CRP in both groups decreased to some extent after 4 weeks, and the level of hs-CRP in the experimental group was significantly lower than that of the control group before and after treatment (P <0.01). Conclusions Atorvastatin can significantly reduce the level of serum hs-CRP in Uighur patients with acute coronary syndromes, which is correlated with the decreasing trend of serum hs-CRP levels in Uighur patients with acute coronary syndrome.